<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772443</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1507301</org_study_id>
    <nct_id>NCT04772443</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in&#xD;
      the patients with dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C levels at week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Change from baseline in LDL-C level at week 8 after administration of the IP</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>DWJ1506</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ1507</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DWC202011</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ1177</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1506</intervention_name>
    <description>DWJ1506</description>
    <arm_group_label>DWJ1506</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1507</intervention_name>
    <description>DWJ1507</description>
    <arm_group_label>DWJ1507</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWC202011</intervention_name>
    <description>DWC202011</description>
    <arm_group_label>DWC202011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1177</intervention_name>
    <description>DWC202011</description>
    <arm_group_label>DWJ1177</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 19 years or over&#xD;
&#xD;
          2. Patients with LDL-C levels â‰¤ 250 mg/dL, TG &lt; 500 mg/dL&#xD;
&#xD;
          3. Subjects who voluntarily decided to participate and provided written consent after&#xD;
             being told of the objectives, method, and effects of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe congestive hear failure&#xD;
&#xD;
          2. Current active liver disease&#xD;
&#xD;
          3. The use of prohibiterd concomitant therapies&#xD;
&#xD;
          4. Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding,&#xD;
             active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is&#xD;
             not controlled by medication, etc.&#xD;
&#xD;
        6.Women who were of childbearing potential without contraception, pregnant, or&#xD;
        breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

